What is ESMFold?

Protein structure prediction underwent a revolution with AlphaFold2's breakthrough at CASP14 in 2020. AlphaFold achieves near-experimental accuracy but requires expensive multiple sequence alignment (MSA) computation as input, which searches databases of related sequences to build evolutionary profiles. ESMFold, published in 2022, takes a fundamentally different approach: it uses a large protein language model (ESM-2, trained on 65 million protein sequences) to encode evolutionary information implicitly within its parameters. This means ESMFold can predict a structure from a single sequence without any database search, reducing inference time from minutes to seconds.

For peptide therapeutics, ESMFold's speed advantage is critical. A pharmacogenomic analysis may generate dozens of candidate peptide sequences that all need structural evaluation. Running AlphaFold on each candidate would take hours; ESMFold processes them in seconds. The model outputs both atomic coordinates and per-residue confidence scores called pLDDT (predicted Local Distance Difference Test). Residues with pLDDT above 70 are considered well-predicted, while regions below 50 are likely disordered. For short therapeutic peptides (8-50 residues), ESMFold's accuracy is sufficient for initial structural screening and binding pose evaluation.

PepFold integrates ESMFold as a core component of its structural analysis layer. After generating peptide candidate sequences from pharmacogenomic variant data, each candidate is submitted to ESMFold for 3D structure prediction. The resulting structures are scored on multiple dimensions including pLDDT confidence, predicted binding geometry, structural stability indicators, and compatibility with the target protein's binding site. Users receive interactive 3D viewers in their analysis reports, allowing visual inspection of each candidate's predicted fold.